Description

NN1177 is a potent long-acting co-agonist that activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This dual activity makes NN1177 a valuable tool for research focused on metabolic regulation, weight management, and energy expenditure. Preclinical studies have shown that NN1177 can induce dose-dependent body weight reduction in diet-induced obese (DIO) mice, highlighting its potential as a research compound in obesity and diabetes models.

As a synthetic peptide designed for extended activity, NN1177 offers researchers a reliable agent for studying pathways related to appetite control, glucose regulation, and lipid metabolism. Its stability and receptor selectivity make it a preferred model compound in endocrine and metabolic research.

Produced under GMP conditions,  is available in bulk for laboratories, research institutions, and wholesale distributors worldwide. It is not intended for human or veterinary use but serves as an essential research tool for investigating dual-receptor agonist mechanisms.

Product Specifications

Mechanism of Action & Research Applications

NN1177 exerts its effects by acting simultaneously on two key receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

• GLP-1 Receptor Activation: By stimulating GLP-1R, NN1177 promotes enhanced insulin secretion in response to glucose, slows gastric emptying, and reduces appetite. These mechanisms are relevant in the study of type 2 diabetes and obesity.

• Glucagon Receptor Activation: GCGR activation increases energy expenditure, promotes lipolysis, and contributes to weight reduction. While glucagon activity alone may raise blood glucose, the combined agonism with GLP-1 helps balance glucose regulation and metabolic output.

• Dual Co-Agonist Potential: By targeting both pathways, NN1177 provides a unique research model for investigating how dual receptor stimulation could deliver superior outcomes compared to GLP-1 agonism alone.

Research Applications Include:

• Preclinical obesity studies using diet-induced obese (DIO) animal models.

• Investigations into metabolic regulation and energy expenditure.

• Research into dual-target therapies for type 2 diabetes and related metabolic disorders.

• Comparative studies against single-pathway GLP-1 receptor agonists.

Development & Research Background

NN1177 represents a class of next-generation incretin-based therapeutic candidates. Traditional GLP-1 receptor agonists have shown strong efficacy in lowering glucose and reducing body weight, but research indicates that combining GLP-1 and glucagon receptor activity may yield more potent effects on energy balance and fat metabolism.

In preclinical models, NN1177 produced dose-dependent weight loss, suggesting enhanced metabolic modulation compared with GLP-1 agonists alone. Its long-acting formulation allows extended activity, making it suitable for studies requiring sustained receptor stimulation.

The compound was developed as part of ongoing research into dual and triple agonists for obesity and diabetes, aiming to address unmet needs in metabolic disease therapy. NN1177 remains an investigational research peptide and is strictly supplied for laboratory use.

Side Effects

In research models, potential effects observed with NN1177 include:

• Gastrointestinal disturbances (nausea-like symptoms in animal studies)

• Alterations in glucose metabolism

• Potential hypoglycemia when combined with other glucose-lowering agents

• Changes in energy expenditure and appetite

These findings are derived from preclinical research only. The relevance to human safety is unknown, as is not approved for therapeutic use.

Disclaimer

 is provided strictly for laboratory research purposes only. It is not intended for human consumption, medical use, or veterinary applications. All handling should be performed by qualified professionals in controlled research environments.

Keywords

 GLP-1/glucagon receptor co-agonist, GLP-1 dual agonist research, obesity research peptide, metabolic disorder peptide, diabetes research peptide, GMP supplier?wholesale NN1177, buy NN1177 peptide